A Nucleic Acid Approach to Antibody Therapeutics

Healthcare7/18/2024 3:00 PM

Go to Registration Page


Monoclonal antibodies represent a highly successful class of therapeutics that are used to treat complex diseases across a wide range of therapeutic areas. However, their high cost and variable patient response underscores the need for new modalities that can be used to activate or suppress the immune system. Aptamers have long been viewed as a simpler alternative to antibodies, but challenges with biostability, effectiveness, and throughput have slowed their progress in the clinic. In this talk, I will discuss a path for democratizing antibody therapeutics that relies a class of molecules called threomers, which are highly functionalized synthetic nucleic acids assembled on a biologically stable threose nucleic acid (TNA) framework. I will describe the underlying chemistry and enzyme engineering developed to support a high throughput discovery pipeline and provide examples of recently discovered threomers that mirror the binding properties of antibodies.

Speaker: John Chaput, PhD, Professor - University of California, Irvine


Rate This Webinar

community rating (0 votes): 
Rate or Review This Webinar


Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics. The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The Annual Meeting is open to anyone interested or involved in oligonucleotide therapeutics. The OTS offers scholarships, awards, and travel grants annually.